Empagliflozin/linagliptin
Empagliflozin/Linagliptin
Empagliflozin/Linagliptin (pronunciation: em-pa-gli-FLOE-zin/lin-a-GLIP-tin) is a combination medication used in the treatment of Type 2 diabetes.
Etymology
The term Empagliflozin is derived from the chemical name of the drug, which is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Linagliptin is derived from the chemical name of the drug, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Usage
Empagliflozin/Linagliptin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke.
Related Terms
- Type 2 diabetes
- Sodium/glucose cotransporter 2 (SGLT2) inhibitors
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Blood sugar
- Heart attack
- Stroke
See Also
External links
- Medical encyclopedia article on Empagliflozin/linagliptin
- Wikipedia's article - Empagliflozin/linagliptin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski